Scil Proteins and Celares Form Marketing Partnership of Protein Production and PEGylation
14 March 2006
Scil Proteins and celares Form Marketing Partnership of Protein Production and PEGylation
Halle (Saale) and Berlin, Germany - March 14, 2006. Scil Proteins Services, a business unit of Scil Proteins GmbH, and celares GmbH have established a business alliance to co-market their services of protein production and protein modification through polyethylene glycol (PEG).The alliance combines the expertise of both and offers customers a one-stop-shop of tailored-made PEGylated proteins.
Therapeutic protein candidates often have to overcome drawbacks such as short half lives and rapid clearance. The method of PEGylation can overcome many of those unwanted properties and can even reduce side effects. PEGylation is currently the first choice of drug optimisation and this technology has proven successful in improving the pharmacokinetic and pharmacodynamic properties of many biopharmaceutical drugs.
This partnership is the perfect link between Scil Proteins Services' skills in protein production in microbial hosts and celares skills in PEGylation. Scil Proteins Services provides the complete package of protein production services. The company develops microbial expression systems, protocols for fermentation, downstreaming and analytical testing and produces recombinant proteins from a mg to g scale. Celares PEGylates the proteins produced by Scil Proteins Services using commonly available PEG moieties or its proprietary highly-branched PEG moieties. Thus, customers can just leave the DNA sequence encoding the protein of interest at the formed consortium and receive the PEGylated drug ready for their studies.
For further information on the service portfolios of the companies visit the respective company's website or arrange a meeting with representatives at the Bio 2006 event in Chicago.
About Scil Proteins GmbH:
Scil Proteins GmbH, based in Halle (Saale), Germany, is a biotechnology company focusing on recombinant proteins. The business unit Scil Proteins Services has established internationally recognized expertise in industrial process development and recombinant protein production using microbial host organisms. Scil Proteins Services offers gene cloning, cell line development, fermentation, in-vitro protein folding, purification, in-process control and analytical testing. The customer base encompasses pharmaceutical and biotech companies in Europe, USA and Japan. Furthermore, Scil Proteins is developing biotherapeutics based on its proprietary Affilin™ technology. Affilin™ molecules are a new generation of human binding proteins.
More information on Scil Proteins is available at www.scilproteins.com.
About celares GmbH:
celares GmbH, based in Berlin, Germany, is a drug delivery company focusing on the PEGylation of biopharmaceuticals. The company possesses a high level of expertise and many years of experience in the areas of polymer chemistry, modification of protein drugs and PEGylation. In addition to its own product line, CelaSYS - a new class of monodispersed PEG moieties, celares offers numerous customized PEGylation services. celares provides screening for optimal PEGylation strategy and reaction conditions, process development, preparation of PEGylated Biopharmaceuticals for in-vitro and in-vivo testing, development of analytical methods, and chemical synthesis of tailor-made PEG reagents. Customers are international pharmaceutical and biotech companies.
More information on celares is available at www.celares.com.
